[천지일보=홍보영 기자] Daewoong Pharmaceutical CEO Jeon Seung-ho participated in the ‘UI Investment & Start Up Forum’ held at the National University of Indonesia (UI) in Indonesia on the 14th in real-time, non-face-to-face. Daewoong Pharmaceutical introduced Indonesia’s projects and future plans, and shared the current status and plans of industry-university-linked open innovation to be promoted with excellent universities and talents.
About 300 people including government officials such as the Indonesian Ministry of Health and Welfare and the head of the Investment Coordination Agency, major academic figures such as the UI President, investors, and local media attended this forum. was composed
In addition, there was also an opportunity to promote mutual cooperation by sharing business and investment strategies of major Indonesian pharmaceutical companies and investors.
Daewoong Pharmaceutical, the only one in Korea to be invited, presented ▲R&D and open innovation direction ▲Indonesia business and research status ▲Daewoong Pharmaceutical’s future business plan in Indonesia.
In this announcement, CEO Jeon Seung-ho announced the global expansion of Daewoong Pharmaceutical’s open innovation with Indonesia as a base country in Southeast Asia. In particular, he emphasized Daewoong Pharmaceutical’s vision for the growth of the Indonesian pharmaceutical industry, continued investment in bio and pharmaceuticals, and plans to strengthen cooperation with talented people. Participants also showed a lot of interest through a number of questions and answers.
Daewoong Pharmaceutical has set open innovation as its core future strategy and has been building a new cooperative model through investment in innovative startups and shared growth. Fields of particular attention are DDS formulation technology, cell and gene therapy, next-generation stem cell platform, neurotoxin, and artificial intelligence (AI).
UI, which hosted this event, is a prestigious university that ranks first in Indonesia in various indicators. Daewoong Pharmaceutical and Daewoong Pharmaceutical are cooperating with each other by jointly establishing a bioprocessing laboratory and a bioanalytical laboratory within the university to share Daewoong Pharmaceutical’s research technology.
In addition, Daewoong Pharmaceutical and UI are maintaining a close cooperative relationship by conducting a global scholarship program and a credit-linked global master’s and doctoral system training program in order to foster talented people who will contribute to the development of the Indonesian pharmaceutical industry.
Daewoong Pharmaceutical is conducting various open innovation projects in Indonesia through its branch office and joint venture Daewoong Infion, including Epodion (erythropoietic hematopoietic agent), EZF (epithelial cell growth factor) biopharmaceutical business, and operation of joint research institutes linked to universities.
Copyright © Cheonji Ilbo – New Era Hope Press Prohibition of unauthorized reproduction and redistribution
/cloudfront-ap-northeast-1.images.arcpublishing.com/chosun/GO66MPSJDSYAMZLAGKMFDK6V3I.jpg?fit=300%2C300&ssl=1)
